|Mr. Douglas M. VanOort||N/A||N/A||62|
|Mr. George A. Cardoza||N/A||N/A||55|
|Mr. Steven C. Jones||N/A||N/A||54|
|Dr. Maher Albitar M.D.||N/A||N/A||62|
|Dr. Steven G. Brodie Ph.D., FACMG||371.54k||344.6k||56|
NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clients oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
NeoGenomics, Inc.’s ISS Governance QualityScore as of October 15, 2017 is 5. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 3; Compensation: 7.